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Deletion of BMP receptor type IB 
decreased bone mass in association 
with compromised osteoblastic 
differentiation of bone marrow 
mesenchymal progenitors
Ce Shi1,2, Ayaka Iura2, Masahiko Terajima3, Fei Liu2, Karen Lyons4,5,6, Haichun Pan2, 
Honghao Zhang2, Mitsuo Yamauchi3, Yuji Mishina2 & Hongchen Sun1
We previously found that disruption of two type I BMP receptors, Bmpr1a and Acvr1, respectively, in 
an osteoblast-specific manner, increased bone mass in mice. BMPR1B, another BMP type I receptor, 
is also capable of binding to BMP ligands and transduce BMP signaling. However, little is known about 
the function of BMPR1B in bone. In this study, we investigated the bone phenotype in Bmpr1b null mice 
and the impacts of loss of Bmpr1b on osteoblasts and osteoclasts. We found that deletion of Bmpr1b 
resulted in osteopenia in 8-week-old male mice, and the phenotype was transient and gender specific. 
The decreased bone mass was neither due to the changes in osteoblastic bone formation activity nor 
osteoclastic bone resorption activity in vivo. In vitro differentiation of Bmpr1b null osteoclasts was 
increased but resorption activity was decreased. Calvarial pre-osteoblasts from Bmpr1b mutant showed 
comparable differentiation capability in vitro, while they showed increased BMP-SMAD signaling 
in culture. Different from calvarial pre-osteoblasts, Bmpr1b mutant bone marrow mesenchymal 
progenitors showed compromised differentiation in vitro, which may be a reason for the osteopenic 
phenotype in the mutant mice. In conclusion, our results suggested that BMPR1B plays distinct roles 
from BMPR1A and ACVR1 in maintaining bone mass and transducing BMP signaling.
Bone morphogenetic proteins (BMPs) were originally identified as factors that can induce the formation of bone 
and cartilage when implanted at ectopic sites1. Recombinant human BMPs, rhBMP-2 and rhBMP-7, have been 
approved by US Food and Drug Administration (FDA) for clinical use of a variety of bone related conditions, 
including non-union, open fractures, joint fusions, aseptic bone necrosis and critical bone defects2. However, how 
BMP regulates bone homeostasis, the variable effects of BMP signaling on different cell types in bone, and how 
BMP signaling is transduced through different BMP receptors, are not fully elucidated yet. Thus, the answers to 
these questions may increase the efficacy of BMP therapeutics and provide new targets of treating bone related 
diseases.
BMPs are members of the transforming growth factor-β (TGF-β ) superfamily. The TGF-β superfamily pro-
teins bind to two types of serine/threonine kinase receptors, i.e. type I and type II receptors3. Both type I and type 
II receptors are required for signal transduction4. Among various type I receptors, ACVR1 (activin receptor type 
I, also known as activin receptor-like kinase 2, ALK2), BMPR1A (BMP receptor type IA, also known as ALK3) 
and BMPR1B (BMP receptor type IB, also known as ALK6) are capable of mediating BMP ligand signal. BMP 
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type I receptors are transphosphorylated by BMP type II receptors upon ligand binding, and then phosphorylate 
the cytoplasmic signaling molecules to initiate SMAD and non-SMAD signaling cascades5.
Previously, we reported that an osteoblast-specific deletion of Bmpr1a or Acvr1 results in increased bone 
mass6–10. Both BMPR1A and ACVR1 in osteoblasts influenced bone modeling and bone remodeling through 
up-regulation of Sost and Dkk1, resulted in the suppression of canonical WNT pathway and the increase of 
RANKL/OPG ratio. Thus the disruption of Bmpr1a or Acvr1 breaks the balance of bone formation and bone 
resorption, i.e. slightly decreased osteoblast activity and dramatically decreased osteoclast activity. BMPR1B, 
another BMP type I receptor, is also capable of binding to BMP ligands and transduce BMP signaling. Unlike 
Bmpr1a or Acvr1 homozygous null mice that show early embryonic lethality11,12, Bmpr1b homozygous null mice 
are viable exhibiting forelimb and hindlimb defects, due to markedly reduced proliferation of prechondrogenic 
cells and chondrocyte differentiation in the phalangeal region13,14. However, the bone phenotype of Bmpr1b null 
mice and the mechanisms of how BMPR1B regulates the activity of osteoblasts and osteoclasts have not been 
studied yet.
In this study, we investigated the bone phenotype of Bmpr1b null mice in vivo and the effects of Bmpr1b dele-
tion on osteoclasts and osteoblastic lineage cells in vitro. We found that deletion of Bmpr1b leads to osteopenia in 
8-week-old male mice, which is likely due to the compromised osteogenic differentiation of bone marrow mes-
enchymal progenitors, but not that of pre-osteoblasts. In addition, we compared BMP-SMAD and non-SMAD 
signaling mediated by different BMP type I receptors and found that deletion of Bmpr1b sensitized BMP-SMAD 
signaling in cultured calvarial pre-osteoblasts, which was different from the other two BMP type I receptors. We 
identified that BMPR1B plays distinct roles in maintaining bone homeostasis and transducing BMP signaling 
compared with ACVR1 and BMPR1A.
Results
Bmpr1b deletion leads to lowered bone mass in mice. Bmpr1b homozygous mutant mice (Bmpr1b−/−, KO) 
and littermate controls (Bmpr1b+/+, WT and Bmpr1b+/−, Het) were born with a normal Mendelian ratio 
(Supplementary Table S1). At newborn stage, no overt histologic differences were found in femur from either 
males or females (Supplementary Fig. S1). At 8 weeks old, KO males weighed slightly but significantly less (10%) 
(p < 0.05) than littermate WT males (Supplementary Fig. S2). However, 8-week-old females had similar body 
weight between WT and KO (Supplementary Fig. S2).
Micro-CT results showed an osteopenic phenotype in 8-week-old KO male mice (Fig. 1A). In femur trabecular 
compartment of KO mice (Fig. 1B–F and Supplementary Fig. S3A,B), we observed a 34% decrease in trabecular 
bone volume fraction (BV/TV) (p < 0.001), a 24% decrease in trabecular thickness (Tb. Th) (p < 0.001), a slight 
increase (8%) in trabecular separation (Tb. Sp) (p < 0.01), and a 23% decrease in bone mineral density (BMD) 
(p < 0.001), but no difference in tissue mineral density (TMD) (p > 0.05). In femur cortical compartment of KO 
mice (Fig. 1G–K and Supplementary Fig. S3C–E), we observed a 25% increase in cortical porosity (1-BV/TV) 
(p < 0.001), a 4% decrease in outer perimeter (p = 0.08), a 11% decrease in cortical thickness (p < 0.05), a slight 
decrease in cortical bone volume fraction (BV/TV) (2.5%) (p < 0.001), a 7% decrease in bone mineral density 
(BMD) (p < 0.05), but no difference in tissue mineral density (TMD) (p > 0.05), and a 13% decrease in cortical 
area (p < 0.05). However, these differences were not seen in 8-week-old females (Supplementary Fig. S4). In 
11-week-old males (Supplementary Fig. S5), although they showed a 25% decrease in trabecular thickness (Tb. 
Th) by static histomorphometry (p < 0.05) (Supplementary Fig. S5R), we did not detect overt differences in all 
trabecular parameters investigated by micro-CT. In the cortical compartment, we detected a slight decrease (8%) 
in bone volume fraction (BV/TV) and a 63% increase in cortical porosity (1-BV/TV) (p < 0.05) by microCT 
(Supplementary Fig. S5G,H). These results suggested that the bone phenotypes observed in Bmpr1b mutant mice 
are gender specific and transient.
Disruption of Bmpr1b does not change osteoblastic bone formation activity or osteoclastic 
bone resorption activity in mice. Next, we performed static (Fig. 1M–R and Supplementary Fig. S3F–H) 
and dynamic (Fig. 1S–V) histomorphometry on distal femora. Using H&E stained sections of 8-week-old sam-
ples (Fig. 1L), we identified a 28% reduction of trabecular thickness (Tb. Th) (Fig. 1O, p < 0.05) as consistent 
with micro-CT data. However, we did not observe overt changes in the other indices of static histomorphometry 
(Fig. 1M–R and Supplementary Fig. S3F–H). We noticed a decreased tendency of bone area (BA/TA) (Fig. 1M, 
p = 0.06) and an increased tendency of trabecular bone separation (Tb. Sp) (Supplementary Fig. S3F, p = 0.09), 
which are also consistent with micro-CT measurements (Fig. 1B,E). In addition, for dynamic histomorphom-
etry (Fig. 1S–V), there was no difference between WT and KO with regard to mineral apposition rate (MAR), 
mineralized surface (MS), or bone formation rate (BFR). Taken together, static and dynamic histomorphemetry 
suggested that the decreased bone mass observed in KO mice is not due to the changes in osteoblast number and 
bone formation function or osteoclast number and bone resorption function in vivo.
To determine serum biological markers for both bone formation and bone resorption, we measured levels 
of N-terminal propeptide of type 1 procollagen (P1NP), collagen type 1 cross-linked C-telopeptide (CTX-1), 
calcium and phosphorus in serum. We found there was no difference between WT and KO (Supplementary Fig. 
S6A–C).
Next, to determine osteogenic capability of osteoblasts in vitro, calvarial pre-osteoblasts were cultured in oste-
ogenic medium. ALP and alizarin red staining showed no difference between WT and KO (Supplementary Fig. 
S7). P1NP level in culture medium was not changed (Supplementary Fig. S6D,E). In calvarial pre-osteoblasts 
treated with or without BMP, there was no difference in the expressions of Bmpr1a and Acvr1 between WT and KO 
(Supplementary Fig. S8), suggesting that Bmpr1b deletion was not compensated by other type I receptors. Moreover, 
there was no difference in the expressions of osteoblast marker genes or genes related with BMP signaling in cul-
tured calvarial pre-osteoblasts (Supplementary Fig. S9) or in tibiae from both males and females (Supplementary 
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Fig. S10). Some genes that regulate WNT signaling show reductions in Bmpr1b KO calvarial pre-osteoblasts (Sost 
and Dkk2 in Supplementary Fig. S9) and 8-week-old males (Lrp5, Sost and Dkk1 in Supplementary Fig. S10), how-
ever, we did not see differences in the WNT target genes (Axin2 and Lef1). These results suggested that deletion of 
Bmpr1b did not change the differentiation ability of calvarial pre-osteoblasts in vitro.
In terms of collagen content and structure both in tibiae and cultured calvarial pre-osteoblasts, there were no 
differences between WT and KO in collagen composition (Supplementary Fig. S11A,D), lysine hydroxylation 
(Supplementary Fig. S11B,E), or collagen cross-links (Supplementary Fig. S11C,F). In addition, there was no con-
sistent difference between WT and KO in gene expression levels of collagen modifying enzymes (Supplementary 
Fig. S12). These results suggested that deletion of Bmpr1b did not change the collagen deposition by osteoblasts 
or the post-translational modifications of collagen both in- and out-side of osteoblasts.
To determine osteoclast activity in vitro, we investigated the proliferation and differentiation of osteoclast pre-
cursors, and survival and bone resorption function of mature osteoclasts. After osteoclast precursors were treated 
with M-CSF only, there were more cells in KO compared with WT (Fig. 2A), indicating that osteoclast precursors 
from KO mice either have a higher proliferation rate or a lower apoptosis. When treated with M-CSF and gradi-
ent concentrations of RANKL, WT and KO osteoclast precursors showed different responses to RANKL. When 
RANKL was at low concentration (10 ng/ml), there were more KO osteoclasts compared with WT. As RANKL 
concentration increased, there were fewer KO osteoclasts compared with WT (Fig. 2B). As shown in Fig. 2C, KO 
Figure 1. Bmpr1b deletion leads to osteopenia in 8-week-old male mice, but does not change osteoblastic 
bone formation activity or osteoclastic bone resorption activity in vivo. (A) Representative micro-CT 
images of trabecular compartment of distal femur and cortical compartment of middle femur from 8-week-
old males. (B–F) Trabecular parameters were determined by micro-CT for the femora from 8-week-old male 
mice: (B) trabecular bone volume fraction (bone volume/tissue volume, BV/TV); (C) trabecular number  
(Tb. N); (D) trabecular thickness (Tb.Th); (E) trabecular separation (Tb. Sp); (F) tissue mineral density 
(TMD); (G–K) Cortical parameters: (G) cortical porosity; (H) inner perimeter; (I) outer perimeter; (J) cortical 
thickness; (K) TMD. For each group, n = 8. (L–R) Static histomorphometry for the trabecular compartment of 
distal femora of 8-week-old male mice (for each group, n = 6): (L) Representative H&E stained sections;  
(M) trabecular bone area/tissue area (BA/TA); (N) trabecular bone number (Tb. N); (O) trabecular bone 
thickness (Tb. Th); (P) osteoblast number per bone surface (N. Ob/BS); (Q) osteoclast number per bone 
surface (N. Oc/BS); (R) eroded surface per bone surface (ES/BS); (S) Representative calcein labeling images  
(5 days apart between two labels). (T–V) Dynamic histomorphometry for the femora of 8-week-old male mice 
(for each group, n = 8): (T) mineral apposition rate (MAR); (U) mineralized surface per bone surface  
(MS/BS); (V) bone formation rate (BFR/BS). *p < 0.05; **p < 0.01. WT: wild type; KO: knockout.
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osteoclasts were much larger with more nuclei than WT osteoclasts, thus there were not enough spaces for more 
osteoclasts formation when RANKL concentration was increased. It suggested that KO osteoclast precursors 
were more sensitive to RANKL and had an increased fusion into multinucleated osteoclasts. After differentiation 
factors were removed, we observed there were more KO osteoclasts left compared with WT, especially at 12 h 
and 24 h after removal of the cytokines (Fig. 2D). These data suggested that BMP signaling through BMPR1B 
somehow affects osteoclast apoptosis. When osteoclasts were differentiated on inorganic hydroxyapatite coated 
surface, KO osteoclasts showed decreased resorption area as well as decreased resorption area per osteoclast 
(Fig. 2E). Taken together, in vitro results revealed increased number of osteoclast precursors, more osteoclast dif-
ferentiation, longer survival and decreased resorption function from KO mice. However, these in vitro data were 
inconsistent with the in vivo static histomorphometry, which showed no difference in osteoclast number, osteo-
clast surface, or eroded surface (Fig. 1Q,R and Supplementary Fig. S3H) (See discussion). Taken together, these 
results suggested that the osteopenic phenotype observed in KO mice was not due to the changes in osteoblastic 
bone formation activity or osteoclastic bone resorption activity.
Disruption of Bmpr1b alters BMP signaling pathway in calvarial pre-osteoblasts distinctly from 
disruption of Bmpr1a or Acvr1. To investigate the regulation of BMP signaling mediated by BMP type I 
receptors, phosphorylation levels of SMAD1/5/9 (SMAD signaling) and ERK1/2 and P38 (non-SMAD signaling) 
in calvarial pre-osteoblasts were determined by western blot. Surprisingly, we found that deletion of Bmpr1b 
resulted in a higher level of p-SMAD1/5/9 at early time points upon BMP stimulation (1 min and 5 min), and 
the peak level of p-SMAD occurred earlier in KO cells, whereas P-ERK1/2 and P-P38 levels showed decreased 
tendency in KO cells compared with WT (Fig. 3A,B).
To determine whether the elevated P-SMAD1/5/9 can translocate into nucleus, we performed immunocy-
tochemistry using calvarial pre-osteoblasts. The results showed that nuclear signal of P-SMAD1/5/9 was very 
weak without BMP stimulation, and total Smad was mainly distributed in the cytoplasm. After BMP stimulation, 
P-SMAD1/5/9 in both WT and KO cells can translocate into nucleus (Fig. 3E). At 5 min after BMP stimulation, 
the nuclear signal of P-SMAD1/5/9 was stronger in KO cells than that in WT (Fig. 3F), demonstrating that the 
elevated P-SMAD1/5/9 in Bmpr1b KO cells can translocate into nucleus. The questions that why P-SMAD level is 
higher in KO pre-osteoblasts and why higher level of BMP-SMAD signaling does not influence the expressions of 
osteoblast marker genes and osteoblast differentiation ability need to be further addressed.
Figure 2. In vitro differentiation of osteoclasts from KO mice is increased but resorption activity is 
decreased. (A) Osteoclast precursors were treated with 30 ng/ml M-CSF for 6 days, and the number of cells 
was counted. (B) Osteoclasts precursors were prompted differentiation with gradient concentration of RANKL 
for 6 days. Cells were stained with TRAP, and the number of osteoclasts (B) as well as the number of nuclei per 
osteoclasts (C) were counted. (C) Representative images of osteoclast differentiation from WT and KO mice. 
(D) Osteoclasts precursors were differentiated with 30 ng/ml M-CSF and 50 ng/ml RANKL. On day 6, M-CSF 
and RANKL were removed from the culture, and number of osteoclasts was counted at indicated time points. 
The numbers of osteoclasts at each time point was normalized to that at time point 0. (E) Osteoclast precursors 
were cultured on coated surface and treated with 30 ng/ml M-CSF and 50 ng/ml RANKL. After 6 days, the area 
of resorption was measured and the number of osteoclasts on coated surface was counted. Resorption area was 
normalized by osteoclast number. Representative images of resorption by WT and KO osteoclasts. *p < 0.05; 
**p < 0.01. WT: wild type; KO: knockout.
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Figure 3. Deletion of Bmpr1b transduces BMP signaling pathway distinctly in calvarial pre-osteoblasts. 
(A) Cultured calvarial pre-osteoblasts from WT and KO were serum starved overnight, followed by rhBMP-2 
stimulation for the indicated times. Cells were lysed and immunoblotted with P-SMAD1/5/9, P-ERK1/2 
and P-P38. GAPDH, ERK1/2 and P38 were used as loading controls. (B) Quantification of the blotting of 
P-SMAD1/5/9, P-ERK1/2 and P-P38. (C) Cultured calvarial pre-osteoblasts from Acvr1 fx/+ :Ubi Cre-
ERTM (+ )/(− ):R26R/+ (con) and Acvr1 fx/-:Ubi Cre-ERTM (+ )/(− ):R26R/+ (mut) were treated with TM 
and sorted as mentioned in materials and methods section. Cell lysate was immunoblotted as mentioned 
above. (D) Cultured calvarial pre-osteoblasts from Bmpr1a fx/+ :Ubi Cre-ERTM (+ )/(− ):R26R/+ (con) and 
Bmpr1a fx/-:Ubi Cre-ERTM (+ )/(− ):R26R/+ (mut) were treated with TM. Cell lysate was immunoblotted 
as mentioned above. (E) Cells were fixed and immunostained with P-SMAD1/5/9 and SMAD. (F) The mean 
density of P-SMAD1/5/9 signal in the nucleus and the signal ratio of nucleus and cytoplasm of total SMAD 
were quantified. *p < 0.05; **p < 0.01. WT: wild type; KO: knockout; con: control (fx/+ :Ubi Cre-ER(+ )/
(− ):R26R/+ ); mut: mutant (fx/-:Ubi Cre-ER(+ )/(− ):R26R/+ ). For western blot results, the gels were run, 
and transferred to the membrane under the same experimental conditions, and the blots within comparisons 
were exposed at the same conditions. The blots were cropped. Full-length blots are presented in Supplementary 
Figure S13.
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We also examined the impacts of loss of other type I BMP receptors, ACVR1 and BMPR1A. In Acvr1 KO 
calvarial pre-osteoblasts, P-SMAD1/5/9 level was slightly decreased, while there were no obvious changes in the 
levels of P-ERK1/2 and P-P38 (Fig. 3C). In Bmpr1a KO calvarial pre-osteoblasts, there was dramatic decrease 
in the levels of P-SMAD1/5/9 and P-ERK1/2, while there was no overt change in P-P38 level (Fig. 3D). Taken 
together, these results demonstrated that BMPR1B plays distinct roles from BMPR1A and ACVR1 in transducing 
BMP signaling in calvarial pre-osteoblasts.
Osteoblastic differentiation of bone marrow mesenchymal progenitors is compromised in 
Bmpr1b KO mice. To further determine the reason why Bmpr1b KO mice show the osteopenic phenotype, 
we investigated the effect of Bmpr1b deletion on osteoblastic differentiation of bone marrow mesenchymal pro-
genitors in vitro. Bone marrow cells from the KO mice showed significantly less ALP staining after differentiation 
was prompted by BMP at day 7 (Fig. 4A). At 14 days without BMP stimulation, KO cells showed significantly 
less ALP staining (Fig. 4B). Alizarin red staining pattern revealed that KO cells in the absence of BMP have 
less mineralized nodules, while there was no difference after stimulation of differentiation using BMP (Fig. 4C). 
Different from calvarial pre-osteoblasts, these results suggested that deletion of Bmpr1b compromised osteoblas-
tic differentiation of bone marrow mesenchymal progenitors, which may be one of the potential reasons leading 
to osteopenic phenotype.
To obtain the molecular insight of osteoblastic differentiation of bone marrow mesenchymal progenitors, 
gene expression pattern and BMP signaling were examined. Quantitative RT-PCR results showed that in bone 
marrow mesenchymal progenitors, the expressions of Runx2, Sp7, Alpl, Bglap, Dmp1, Ibsp and Col1a2 during the 
culture period were dramatically decreased in Bmpr1b KO cells compared with WT cells (Fig. 5A–G). Different 
from calvarial pre-osteoblasts, deletion of Bmpr1b in bone marrow mesenchymal progenitors showed significant 
decreased P-SMAD1/5/9 in KO cells, compared with WT, while no overt changes in P-ERK1/2 or P-P38 levels 
(Fig. 6A,B). We also examined the impacts of loss of other BMP type I receptors in bone marrow mesenchymal 
progenitors. In Bmpr1a KO bone marrow mesenchymal progenitors, there was a dramatic decrease in the level of 
P-SMAD1/5/9, whereas there were no overt changes in the levels of P-ERK1/2 and P-P38 (Fig. 6C,D). In Acvr1 
KO bone marrow mesenchymal progenitors, there was a slight decrease in the level of P-SMAD1/5/9 at early 
time points upon BMP stimulation, whereas there were no overt changes in the levels of P-ERK1/2 and P-P38 
(Fig. 6E,F).
To examine the expression pattern of the three BMP type I receptors in different types of cells or tissues, quan-
titative RT-PCR was performed. We found the expression levels of Bmpr1b were similar among different cells 
types, but much lower compared with Acvr1 or Bmpr1a (Fig. 6G). However, the expression levels of Bmpr1a and 
Figure 4. Osteoblastic differentiation of bone marrow mesenchymal progenitors is compromised in KO 
mice. Bone marrow mesenchymal progenitors were isolated from femora and tibiae of 8-week-old mice and 
subjected to osteoblast differentiation. Cells were treated with or without BMP-2. (A) Alkaline phosphatase 
(ALP) staining and mean density of the staining after 7 days of differentiation. (B) ALP staining and mean 
density of the staining after 14 days of differentiation. (C) Alizarin red staining and quantification of the staining 
after 21 days of differentiation. After staining, 300 μl/well of 10% CPC was used to dissolve bound alizarin red S. 
The dissolved solution was diluted 10 times with 10% CPC before measurement. *p < 0.05; **p < 0.01. WT: wild 
type; KO: knockout.
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Acvr1 are more than 3 folds lower in bone marrow mesenchymal progenitors than those in calvaria, leading to a 
significantly higher ratio of Bmpr1b in bone marrow mesenchymal progenitors (Fig. 6G). These results suggested 
that deletion of Bmpr1b may affect more in behavior of bone marrow mesenchymal progenitors, but not calvarial 
pre-osteoblasts.
Taken together, these results indicated that different from calvarial pre-osteoblasts, osteoblastic differentiation 
of bone marrow mesenchymal progenitors from Bmpr1b KO mice was compromised, which may be due to the 
less capability to transduce BMP signaling and the subsequent gene transcription.
Discussion
Our present results demonstrated that deletion of Bmpr1b leads to osteopenia in 8-week-old male mice. The 
osteopenic phenotype may be due to the compromised osteoblastic differentiation of bone marrow mesenchy-
mal progenitors. Deletion of Bmpr1b did not change osteoclast behavior in vivo, while in vitro differentiation 
of Bmpr1b KO osteoclast was increased but resorption activity was decreased. In addition, deletion of Bmpr1b 
resulted in increased phosphorylation level of SMAD1/5/9 and its nuclear translocation at early time points upon 
BMP stimulation in calvarial pre-osteoblasts. Our results suggested that BMPR1B plays distinct roles in maintain-
ing bone homeostasis and transducing BMP signaling. Based on our previous and current findings, we proposed 
a working model (Fig. 6H), showing distinct roles of BMP type I receptors during osteoblastic differentiation 
from bone marrow mesenchymal progenitors.
Although BMPR1B and BMPR1A share a high degree of sequence similarity, and have overlapping functions 
in chondrogenesis15, several studies indicated that they may possess distinct biological functions16–18. Our group 
showed that deletion of Bmpr1a using Og2-Cre show alterations in bone remodeling in an age-dependent manner6. 
We also found that deletion of Bmpr1a using a 3.2-kb Col1-CreER increases bone mass at both postnatal stage 
(3- and 22-week-old)8,9 and embryonic stage7, due to decreased osteoblast activity and more dramatically 
decreased osteoclast activity. BMPR1A in osteoblasts influenced bone modeling and bone remodeling through 
up-regulation of Sost and Dkk1, resulted in the suppression of canonical WNT pathway and the increase of 
RANKL/OPG ratio. Similarly, deletion of Acvr1 using a 3.2-kb Col1-CreER increased bone mass at an embryonic 
stage (E18.5) and adult stage (3-week-old) in association with increased canonical WNT signaling via suppres-
sion of Sost and Dkk110. Taken together, disruption of Bmpr1a or Acvr1 leads to imbalance between bone forma-
tion and bone resorption resulting in an increase of bone mass. Early studies using 2T3 cell line also suggest that 
BMPR1A and BMPR1B mediate different signals responsible for osteoblast differentiation19. Overexpression of 
truncated BMPR1A in 2T3 cells enhances bone matrix formation in the absence of BMP-2, whereas overexpres-
sion of truncated BMPR1B completely blocks BMP-2-induced mineralized bone matrix formation, and expres-
sion of constitutively active BMPR1B induces mineralized bone matrix formation without addition of BMP-219. 
In the current study, we demonstrated that deletion of Bmpr1b showed opposite bone phenotype compared 
from disruption of Acvr1 or Bmpr1a. However, we observed the osteopenic phenotype only in males, but not in 
females. One possible explanation is the difference in hormonal regulation between the genders20. The other pos-
sibility is the difference in adaptation between the genders, e.g. bones in different genders respond differently to 
exercise21,22. In addition, the trabecular bone phenotypes we found appeared within a short time window (only at 
8-week-old, but not at new born stage or 11-week- old) (Supplementary Figs S1 and S5). These findings suggested 
that the bone phenotype in Bmpr1b null mice is gender- and age-dependent.
Figure 5. Expression of osteoblast marker genes was decreased in KO bone marrow mesenchymal 
progenitors. Bone marrow cells were cultured in osteogenic medium for the indicated days. Total mRNA was 
isolated, and quantitative RT-PCR was performed. Expression of Runx2 (A), Sp7 (B), Alp1 (C), Ocn (D), Dmp1 
(E), Ibsp (F) and Col1a2 (G) was calculated. *p < 0.05; **p < 0.01. WT: wild type; KO: knockout.
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Figure 6. BMP signaling was decreased in bone marrow mesenchymal progenitors deficient for Bmpr1b 
(A,B), Bmpr1a (C,D) and Acvr1 (E,F), respectively. (A,C,E) Bone marrow mesenchymal progenitors were 
serum starved overnight, followed by rhBMP-2 stimulation for the indicated times. Cells were lysed and 
immunoblotted with P-SMAD1/5/9, P-ERK1/2 and P-P38. GAPDH, ERK1/2 and P38 were used as loading 
controls. The gels were run, and transferred to the membrane under the same experimental conditions and 
the blots within comparisons were exposed at the same conditions. The blots were cropped. Full-length blots 
are presented in Supplementary Fig. S13. (B,D,F) Quantification of the blotting of P-SMAD1/5/9, P-ERK1/2 
and P-P38. (G) Expression pattern of Bmpr1a, Acvr1 and Bmpr1b in bone marrow mesenchymal progenitors, 
calvaria and cartilage. (H) A working model showing distinct roles of BMP type I receptors during osteoblastic 
differentiation from bone marrow mesenchymal progenitors. Our previous findings demonstrated that 
BMPR1A and ACVR1 in osteoblasts positively regulate osteoblast activity and osteoclast activity. Our current 
study found that BMPR1B positively regulate early osteoblastic differentiation of bone marrow mesenchymal 
progenitors, but not later stage. However, we still do not know how BMPR1A and ACVR1 regulate BMSCs, due 
to lack of mouse model targeting BMPR1A and ACVR1 in BMSCs. *p < 0.05; **p < 0.01. WT: wild type; KO: 
knockout; con: control (fx/+ :Ubi Cre-ER(+ )/(− ):R26R/+ ); mut: mutant (fx/-:Ubi Cre-ER(+ )/(− ):R26R/+ ); 
Het: heterozygous (fx/− :Ubi Cre-ER(− )/(− ):R26R/+ ); BM: bone marrow mesenchymal.
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Different from BMPR1A and ACVR1, deletion of Bmpr1b did not change osteoblast activity or osteoclast 
activity in vivo (Fig. 1). In addition, deletion of Bmpr1b did not result in consistent changes of expressions of 
osteoblast/osteoclast marker genes, or genes related with BMP and WNT signaling in cultured pre-osteoblasts 
and tibiae (Supplementary Figs S9 and S10). However, deletion of Bmpr1b compromised the differentiation ability 
of bone marrow mesenchymal progenitors towards osteoblasts in vitro (Figs 4 and 5). Our results suggested that 
BMPR1B has distinct functions in bone compared with ACVR1 and BMPR1A. The distinct biological functions 
may be due to the expression pattern of the three BMP type I receptors. Bmpr1a and Acvr1 are widely expressed 
in a variety of tissues during development and in multiple adult tissues23,24. In contrast, the expression of Bmpr1b 
is restricted in early mesenchymal cells and differentiated chondrocytes23,25. Our results suggested that the relative 
expression ratios between Bmpr1b and the other BMP type I receptors were much higher in bone marrow mes-
enchymal progenitors compared with those in calvaria (Fig. 6G). This may be the reason why deletion of Bmpr1b 
predominantly influences mesenchymal progenitors, but not calvarial pre-osteoblasts.
It has been reported that there are skeletal stem cells (SSCs) residing in the bone marrows, composing a very 
small portion of the bone marrow (CD45− , TER119− , Tie2− , alphaV+ , Thy− , 6C3− , CD105− , CD200+ ; 
alternatively, CD45− , CD31− , Ter119− , CD105+ , Grem1+ ), which are self-renewing, multipotent progenitors 
for skeletal lineages, which can give rise to cartilage, bone, and stroma26–28. SSCs exist in both fetal and postnatal 
mice, including new born and adult stages26. The bone marrow mesenchymal progenitors used in the current 
study are from flushed bone marrows, thus it is likely that the cells we analyzed in Figs 4–6 contain SSCs. Since 
SSCs express BMP ligands and receptors (including Bmpr1b), it is a formal possibility that BMPR1B may play 
a critical role in this population to maintain bone mass. However, little is known how BMP signaling regulates 
functions of SSCs. It is an interesting and important future endeavor to examine the role of BMP signaling in this 
specific cell population that may be responsible for the transient bone phenotype in the Bmpr1b mutant mice.
We need to be mindful to consider differences in the genetic models when functions of BMPR1B in skel-
etogenesis are compared with those of other type I BMP receptors. Here, we analyzed bone phenotypes 
found in conventional mutant mice for Bmpr1b, whereas we previously reported bone phenotypes found in 
osteoblast-specific mutant mice for Bmpr1a or Acvr16–10, since conventional mutations for these genes cause early 
embryonic lethality11,12. First, since osteoblast-specific promoters such as 3.2-kb Col1 and Og2 were used to drive 
Cre in these cases, it is unlikely that bone marrow mesenchymal progenitors fully lose BMPR1A or ACVR1 sign-
aling activity. Thus, it is still possible that if appropriate Cre mouse lines were used that direct Cre activity in bone 
marrow mesenchymal progenitors, conditional KO mice for Bmpr1a or Acvr1 might develop osteopenic pheno-
types similar to those found in Bmpr1b mutant mice. Our western blot results support this hypothesis; deletion of 
each of the three BMP type I receptors results in decreased P-SMAD1/5/9 levels, especially in the case of Bmpr1a 
(Fig. 6A–F). Second, in Bmpr1b KO mice we analyzed here, all types of cells including osteoblasts and osteo-
clasts lose BMPR1B signaling. As we reported, BMP signaling in osteoblasts influences osteoclast differentiation 
in vivo7. The inconsistency of osteoclast behavior observed from in vitro and in vivo in our current study may be 
explained by the facts that Bmpr1b KO osteoclasts in vivo may receive signals from Bmpr1b KO osteoblasts to 
show different characteristics found in culture. Interestingly, we reported that osteoblastic bone formation activity 
is increased in the osteoclast-specific KO for Bmpr1a mice even though osteoblasts in these mice remain as WT29. 
These data suggest that BMP signaling in osteoclasts somehow influences osteoblast functions. Thus it is possible 
to speculate that Bmpr1b mutant osteoblasts may be influenced by Bmpr1b osteoclasts in vivo. Nonetheless, we 
clearly demonstrated that BMP signaling through three different type I BMP receptors show different responses 
in their SMAD signaling activity in primary calvarial pre-osteoblasts when prompted by BMP ligands in culture 
(discussed further below). This is an interesting future investigation to uncover molecular mechanisms of how 
BMPR1B signaling regulates osteoblast-osteoclast communication.
It is surprising that deletion of Bmpr1b in calvarial pre-osteoblasts sensitized the cells to BMP stimulation 
to reach the peak level of P-SMAD1/5/9 at 5 min after BMP stimulation, while the increased P-SMAD1/5/9 
did not lead to increased expression of osteoblast differentiation marker genes, despite the fact that increased 
P-SMAD1/5/9 translocated into nucleus (Fig. 3, Supplementary Figs S9 and S10). One potential explanation is 
an effect of phosphorylation of a linker region of R-SMADS. It is known that phosphorylation of a linker region 
of R-SMADS by MAPKs suppresses their translocation to the nucleus and transcriptional activity30. Our results 
showed that the level of P-ERK1/2 in Bmpr1b KO cells was lower at early time points upon BMP stimulation. 
Thus it is possible that decreased level of P-ERK1/2 in KO cells resulted in decreased phosphorylation of linker 
region of R-SMADS, resulting in higher level of P-SMAD nuclear translocation. Another possible explanation is 
an involvement of inhibitory SMADS (I-SMADS) or transcriptional repressors in the nucleus. I-SMADS inhibit 
TGF-β /BMP signaling by interacting with SMAD DNA-binding partners or binding to SMAD-responsive ele-
ments directly, thus inhibiting the formation of SMAD-dependent transcription complexes and TGF-β /BMP 
mediated gene activation31–34. Transcriptional repressing factors Ski and SnoN disrupt the formation of functional 
SMAD-DNA complex and thereby inhibit target gene expression35. BMPR1B signaling may be involved in some 
of those mechanisms, however, further investigations are necessary to draw any conclusions.
In summary, our study identified the role of BMPR1B in bone, which is distinct from BMPR1A and ACVR1. 
We demonstrated that deletion of Bmpr1b inhibited early osteoblastic differentiation of bone marrow mesenchy-
mal progenitors, probably being one of the reasons leading to osteopenic phenotype. We also found a distinct role 
of BMPR1B in transducing BMP signaling in calvarial pre-osteoblasts. This study provides a novel insight into 
the regulation of bone remodeling.
Methods
Mice. Heterozygous Bmpr1b null mice (Bmpr1b+/−)13 were bred to generate homozygous mutant mice 
(Bmpr1b−/−) on the mixed background (129/SvEv × C57B1/6 J). Both wild type (Bmpr1b+/+) and mutant 
(Bmpr1b−/−) animals within the same littermates were sacrificed at newborn stage, 8 or 11 weeks old. 
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Homozygous floxed mice for Bmpr1a or Acvr1 that were also homozygous for ROSA26 reporter (R26R) were 
bred with ubiquitin (Ubi) Cre-ERTM transgenic mice (No. 008085, The Jackson Laboratory) that were also hete-
rozygous null for Bmpr1a or Acvr111,12,36–38. All animal experiments were performed in accordance with the policy 
and federal law of judicious use of vertebrate animals as approved by the University Committee on Use and Care 
of Animals (UCUCA) at University of Michigan.
Micro-computed tomography (micro-CT). Femora were embedded in 1% agarose39 and placed in a 
19 mm diameter tube and scanned over the entire length of the bones using a micro-CT system (μCT100 Scanco 
Medical, Bassersdorf, Switzerland). Scan settings were: voxel size 10 μm, medium resolution, 70 kVp, 114 μA, 
0.5 mm AL filter, and integration time 500 ms. A 0.5 mm region of trabecular compartment was analyzed imme-
diately below the growth plate using a fixed global threshold of 26% (260 on a grayscale of 0–1000, or 569 mg 
HA/ccm); and a 0.3 mm region of cortical compartment around the midpoint was analyzed using a fixed global 
threshold of 36% (360 on a grayscale of 0–1000, or 864 mg HA/ccm). Trabecular bone volume fraction (BV/TV), 
trabecular thickness (Tb. Th), trabecular number (Tb. N), trabecular separation (Tb. Sp), cortical bone volume 
fraction (BV/TV), and cortical porosity (1-BV/TV) were analyzed using the manufacturer’s evaluation software.
Histology and histomorphometry. For hematoxylin and eosin (HE) and tartrate-resistant acid phos-
phatase (TRAP) staining, femora were fixed in 4% paraformaldehyde, decalcified with 10% EDTA, and embedded 
in paraffin. Longitudinal sections of femora were made at 7 μm, and stained for HE and TRAP.
Static histomorphometry was performed on sections taken from the femora in a blinded, nonbiased manner 
using Image J (1.49P). Regions of interest (ROIs) were confined to the secondary spongiosa and restricted to a 
square area (1.1 mm in length and width) 300 μm proximal to the growth plate of the distal femora.
For dynamic histomorphometry, 8-week-old mice were given calcein (0.01 mg/g) in 2% NaHCO3 intraperi-
toneally 7 and 2 days before dissection. Femora were dissected and fixed in 4% paraformaldehyde. The undecal-
cified femora were embedded in 8% gelatin and 10 μm longitudinal sections were made. The measurements were 
performed at distal femur trabecular bone.
All static and dynamic parameters were measured according to the Report of the American Society of Bone 
and Mineral Research Histomorphometry Nomenclature Committee40.
Calvarial pre-osteoblast culture and BMP stimulation. Primary calvarial pre-osteoblasts were isolated 
from 1- to 3-day-old mice as reported41. For osteogenic differentiation, cells were seeded at 2.5 × 104 cells/cm2 
and allowed for adhesion in α -MEM containing 10% fetal bovine serum (FBS, Denville) overnight. On the 
second day, the medium was changed to differentiation medium (DM) (α -MEM containing 10% FBS, 10 mM 
β -glycerophosphate (Sigma-Aldrich) and 50 μg/ml L-ascorbic acid (Sigma-Aldrich)) either with or without 
100 ng/ml recombinant human bone morphogenetic protein 2 (rhBMP-2, R&D Systems) for the indicated days 
and stained for alkaline phosphatase and alizarin red.
To stimulate BMP signaling, cells were starved (α -MEM containing 0.5% FBS) overnight before treatment 
with 100 ng/ml rhBMP-2 for the indicated times. Then the cells were fixed for immunocytochemistry or lysed for 
protein harvest.
Isolation and culture of bone marrow mesenchymal progenitors. Bone marrow mesenchymal pro-
genitors were isolated from femora and tibiae of 8-week-old mice as reported41. Differentiation and BMP stimu-
lation of bone marrow mesenchymal progenitors was performed as mentioned above.
Tamoxifen treatment and cell sorting. Calvarial pre-osteoblasts and bone marrow mesenchymal pro-
genitors were harvested from Bmpr1a or Acvr1 fx/+ :Ubi Cre-ERTM (+ )/(− ):R26R/+ and fx/− :Ubi Cre-ERTM 
(+ )/(− ):R26R/+ mice. To disrupt Bmpr1a or Acvr1 in culture, Ubi Cre-ERTM activity was induced by adminis-
tering 100 ng/ml of (Z)-4-hydroxytamoxifen (TM) (Sigma-Aldrich) for 6 days8. To isolate Cre-dependent recom-
bined populations, cells were then stained with fluorescein di β -D-galactopyranoside (FDG) (Invitrogen). The 
cells with the Acvr1 or Bmpr1a gene recombined by Cre activity became positive for fluorescence (514 nm), while 
those without recombination were negative. The cells were sorted for fluorescence positive populations using 
a FACSAria III cell sorter. Fx/+ fluorescence positive populations were used as controls, and fx/- fluorescence 
positive populations were used as mutants.
Isolation and culture of osteoclasts. Bone marrow cells were obtained by flushing from femora of 
8-week-old mice42. After cultured overnight in α -MEM containing 10% FBS (Denville), non-adherent cells were 
harvested as bone marrow mononuclear cells (BMMCs). BMMCs were cultured with 30 ng/ml Recombinant 
Murine Macrophage Colony Stimulating Factor (rmM-CSF) (PEPROTECH) to proliferate, and cells at this stage 
were used as osteoclast precursors. To generate mature osteoclasts, osteoclast precursors were cultured with 
30 ng/ml M-CSF and 50 ng/ml Recombinant Murine soluble Receptor Activator of NF-κ B Ligand (rmRANKL) 
(PEPROTECH)43. Medium was changed every other day.
To determine the proliferation of osteoclast precursors, BMMCs were cultured with 30 ng/ml M-CSF. After 6 
days of culture, the number of osteoclast precursors was counted. To determine the differentiation of osteoclasts, 
30 ng/ml M-CSF and gradient concentrations of RANKL (10–50 ng/ml) were used. After 6 days of differentiation, 
TRAP staining was performed, and the number of osteoclasts as well as the number of nuclei per osteoclasts were 
counted. To determine the survival of osteoclasts, after 6 days of differentiation using 30 ng/ml M-CSF and 50 ng/
ml RANKL, the medium was removed and the cells were washed twice with α -MEM. Then the cells were contin-
ued culturing in α -MEM without M-CSF and RANKL for the indicated hours, followed by TRAP staining. The 
number of osteoclasts remained in the culture was counted. To determine the bone resorption function of oste-
oclasts, osteoclasts precursors were seeded onto Osteo Assay Surface (Corning) and underwent differentiation 
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using 30 ng/ml M-CSF and 50 ng/ml RANKL. After 6 days of culture, the resorption area was measured and was 
normalized by osteoclast number.
Histochemistry staining of cell cultures. After bone marrow mesenchymal progenitors or calvarial 
pre-osteoblasts were cultured for 7 and 14 days, cells were stained for alkaline phosphatase (ALP) using alkaline 
phosphatase kits (Sigma-Aldrich) according to manufacturer’s instructions. Mean density of the staining was 
measured using Image J. After culturing for 21 days, cells were stained with 40 mM alizarin red S (Sigma-Aldrich) 
for 10 min at room temperature. Ten % w/v cetylpyridinium chloride (Sigma-Aldrich) was used to dissolve bound 
alizarin red S and optical density was measured at 562 nm. Osteoclasts were stained for TRAP using acid phos-
phatase kit (Sigma-Aldrich) according to manufacturer’s instructions. Osteoclasts were defined as TRAP positive 
cells with three or more nuclei.
Immunocytochemistry staining. After BMP stimulation, cells were fixed in 4% PFA at room tempera-
ture for 15 min, permeabilized using 100% methanol at − 20 °C for 10 min. The cells were incubated with rabbit 
anti-pSMAD1/5/9 (1:800, Cat. No. 13820, Cell Signaling Technology), rabbit anti-Smad1/5/9 (1:100, sc-6031-R, 
Santa Cruz Biotechnology) at 4 °C overnight. Alexa Fluor® 594 donkey anti-rabbit IgG (H + L) antibody (1:200, 
Invitrogen) were used as secondary antibody. The staining was mounted with ProLong® Gold antifade reagent 
with DAPI (Invitrogen). The fluorescent images were taken by Olympus DP70 camera with the same exposure 
time in the same experiment. The mean density in the nucleus or cytoplasm was measured using Image J.
Immunoblot analysis. Cells were lysed in RIPA buffer (20 mM Tris-HCl, 0.1% SDS, 1% Triton X-100, 1% 
sodium deoxycholate) containing protease inhibitor (Roche). The resulting lysates were run on 4–15% or 10% 
Mini-PROTEAN® TGXTM Gel (Bio-Rad) and transferred to Amersham Hybond-P membrane (GE Healthcare). 
The following antibodies were used (all are from Cell Signaling Technology): rabbit anti-pSMAD1/5/9 (1:1000, 
Cat. No. 13820), rabbit anti-phospho-p44/42 MAPK (pERK1/2) (1:1000, Cat. No. 4376), rabbit anti-p44/42 
MAPK (ERK1/2) (1:1000, Cat. No. 4695), rabbit anti-phospho-p38 MAPK (1:1000, Cat. No. 4631), rabbit 
anti-p38 MAPK (1:1000, Cat. No. 9212), and rabbit anti-GAPDH (1:2000, Cat. No. 2118). SuperSignal West Pico 
Chemiluminescent substrate (Thermo Scientific) was used to detect bound antibodies.
RNA isolation and quantitative real-time RT-PCR. Total mRNA was isolated from tibiae, cultured 
calvarial pre-osteoblasts or bone marrow mesenchymal progenitors using TRIzol reagent (Life Technologies). 
For quantitative real-time RT-PCR analyses, equal amounts of RNA were reverse-transcribed using Superscript 
III first-strand synthesis System (Invitrogen) with oligo (dT) as a primer. The resulting cDNA templates were 
subjected to quantitative PCR using TaqMan probes (Gapdh: Mm99999915_g1; Runx2: Mm00501578_m1; 
Sp7: Mm00504574_m1; Alpl: Mm00475831_m1; Bglap: Mm01741771_g1; Ibsp: Mm00492555_m1; Dmp1: 
Mm00803833_g1; Col1a2: Mm00483888_m1; Bmpr1b: Mm00432117_m1; Bmpr1a: Mm00477650_m1; 
Acvr1: Mm01331069_m1; Ctnnb1: Mm00483039_m1; Lrp5: Mm01227476_m1; Axin2: Mm00443610_m1; 
Lef1: Mm00550265_m1; Dkk1: Mm00438422_m1; Dkk2: Mm00445025_m1; Sost: Mm00470479_m1; Tnfsf11: 
Mm00441908_m1; Tnfrsf11b: Mm00435452_m1; Id1: Mm00775963_g1; Plod1: Mm01255760_m1; Plod2: 
Mm00478767_m1; Plod3: Mm00478798_m1; Lox: Mm00495386_m1; Loxl1: Mm01145738_m1; Loxl2: 
Mm00804740_m1; Loxl3: Mm01184865_m1; Loxl4: Mm00446385_m1; Mmp9: Mm00442991_m1; Acp5: 
Mm00475698_m1; Ctsk: Mm00484039_m1) by ABI PRISM 7500 (Applied Biosystems). Data were normalized 
to Gapdh expression using the 2−ΔΔCt method.
Statistical analysis. Data were expressed as means ± standard deviation of triplicate measurements with 
all experiments independently repeated at least three times. Unpaired Student’s two-tailed t-tests were used to 
evaluate statistical differences. Values of p < 0.05 were considered significant.
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